कंपनी का अवलोकन
XOMA Royalty Corporation operates as a biotech royalty aggregator with a specific focus on securing economic rights to future milestone and royalty payments derived from commercial products and pre-commercial therapeutic candidates. The entity functions within the Healthcare sector, specifically targeting the Biotechnology industry, which implies a reliance on intellectual property licensing rather than traditional product sales. The company's scale is defined by a market capitalization of $413.00M, annual revenue of $52.15M, and a workforce comprising 14 employees. These financial metrics indicate that the organization maintains a mid-cap valuation while operating with a highly lean operational structure typical of royalty-based business models.
वित्तीय स्वास्थ्य
The company reported revenue of $52.15M, net income of $18.52M, and EBITDA of $14.36M for the trailing twelve months. The significant disparity between the $52.15M revenue and the $18.52M net income reveals a highly efficient cost structure where expenses consume less than one-third of top-line growth. However, the free cash flow stands at -$14,235,375, indicating that current operational cash generation is insufficient to cover capital expenditures or working capital needs, which limits immediate financial flexibility. The gross margin is an impressive 96.7%, suggesting that the cost of goods sold is negligible relative to revenue, a hallmark of royalty aggregation. The operating margin is 15.9%, while the profit margin reaches 60.8%, demonstrating that the company retains a substantial portion of revenue after covering operating expenses and taxes. Despite generating significant earnings, the balance sheet shows total cash of $83.29M against total debt of $131.56M, resulting in a debt-to-equity ratio of 126.54, which characterizes a leveraged financial position. The current ratio of 3.37 suggests robust short-term liquidity, as current assets significantly exceed current liabilities. Furthermore, the return on equity is 34.1% while the return on assets is 2.9%, indicating that while shareholders see high returns on their equity capital, the company's asset base is large and leveraged, diluting the return on the total asset pool.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is 23.74, whereas the forward P/E is 16.20, implying that the market expects earnings growth to significantly outpace current performance levels over the coming year. The price-to-book ratio stands at 4.90, indicating that the stock trades at a substantial premium over its tangible book value, reflecting the high intangible asset value of its patent portfolio. Alternative valuation metrics include a price-to-sales ratio of 7.92 and an EV/EBITDA of 33.50, which suggest the market is willing to pay a high multiple for the company's revenue and earnings relative to its enterprise value. Regarding trading range, the 52-week high is $39.92 and the 52-week low is $18.40, placing the current market price within a wide band of historical volatility. The beta value is 0.68, which signifies that the stock price tends to be less volatile than the broader market, moving at approximately 32% less intensity than the market index.
Growth & Income
Revenue growth year-over-year is recorded at 57.9%, while earnings growth is listed as N/A, suggesting that profitability metrics are either stabilized or not currently calculated in a comparable growth format for this specific period. Since earnings growth data is unavailable (N/A), a direct comparison of earnings versus revenue growth rates is not possible, but the robust revenue expansion indicates successful portfolio expansion or milestone payments. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are retained for reinvestment into the royalty portfolio or debt management rather than distribution to shareholders. Consequently, the overall growth and income profile is characterized by aggressive revenue expansion without income generation via dividends, relying entirely on capital appreciation and future royalty streams to deliver returns to investors.